Pages that link to "Q37158791"
Jump to navigation
Jump to search
The following pages link to Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review (Q37158791):
Displaying 50 items.
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study (Q24658506) (← links)
- Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis (Q26822912) (← links)
- Applications of systems approaches in the study of rheumatic diseases (Q27692558) (← links)
- Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases (Q30009098) (← links)
- Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study (Q30494937) (← links)
- Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFα through combined in silico/in vitro/in vivo screening (Q30855659) (← links)
- Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic (Q30962462) (← links)
- A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model (Q33556114) (← links)
- Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease (Q33781056) (← links)
- 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis (Q34027648) (← links)
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study (Q34092425) (← links)
- Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? (Q34183220) (← links)
- The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies (Q34346198) (← links)
- Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size (Q34445142) (← links)
- Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial (Q34724711) (← links)
- Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis (Q35086227) (← links)
- Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients (Q35176993) (← links)
- Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα (Q35225741) (← links)
- Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study (Q35605438) (← links)
- Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab (Q35610243) (← links)
- Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy (Q35617683) (← links)
- Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors (Q35620336) (← links)
- Activation of NALP1 inflammasomes in rats with adjuvant arthritis; a novel therapeutic target of carboxyamidotriazole in a model of rheumatoid arthritis (Q35846222) (← links)
- Bifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced Arthritis (Q35915683) (← links)
- Spontaneous retrotransposon insertion into TNF 3'UTR causes heart valve disease and chronic polyarthritis (Q35946169) (← links)
- Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. (Q36234050) (← links)
- Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis (Q36480601) (← links)
- Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys (Q36499879) (← links)
- Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis (Q36942978) (← links)
- Actively Targeted Low-Dose Camptothecin as a Safe, Long-Acting, Disease-Modifying Nanomedicine for Rheumatoid Arthritis (Q37213189) (← links)
- Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis (Q37301126) (← links)
- Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. (Q37390458) (← links)
- G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis (Q37607068) (← links)
- Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab (Q37703466) (← links)
- Rheumatoid arthritis therapy: advances from bench to bedside (Q37739480) (← links)
- Biologics in children's autoimmune disorders: efficacy and safety (Q37765830) (← links)
- Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer (Q37773243) (← links)
- Assessing response and loss of response to biological therapies in IBD. (Q37856191) (← links)
- Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases (Q37953309) (← links)
- Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis (Q37960539) (← links)
- When is switching warranted among biologic therapies in rheumatoid arthritis? (Q38027571) (← links)
- The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists (Q38033127) (← links)
- Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis (Q38053455) (← links)
- Treat-to-target: a tailored treatment approach to rheumatoid arthritis (Q38125456) (← links)
- Emerging role of endosomal toll-like receptors in rheumatoid arthritis (Q38182971) (← links)
- Emerging immunotherapies for rheumatoid arthritis. (Q38188862) (← links)
- Factors affecting response to biologic treatment in psoriasis. (Q38232919) (← links)
- Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides (Q38238931) (← links)
- Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics (Q38988559) (← links)
- Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (Q39173670) (← links)